

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

[Translation]

December 23, 2022

To Shareholders,

Company Name: Renascience Inc.

Name of Representative: Koji Naito, President & CEO
(Code: 4889 TSE Growth)

Inquiries: Hiroyasu Ishimaru, Corporate Officer in charge of
Administration and Corporate Planning

Announcement of Collaboration Agreement with Kyoto University

The Company hereby announced that the Company has resolved to enter into a collaboration agreement (the "Agreement") with Kyoto University to investigate the efficacy and safety of RS5614, a plasminogen activator inhibitor 1 (PAI-1) inhibitor, for the treatment of acute exacerbation of idiopathic interstitial pneumonia .

Although this matter does not meet the category of timely disclosure as stipulated by the rules of the Tokyo Stock Exchange, the Company considers the information is of value to the Shareholders, and therefore discloses this information voluntarily.

1. Background and outline of the Agreement

RS5614, PAI-1 inhibitor, may be effective in the treatment of interstitial pneumonia, since it inhibits thrombosis, inflammation, and fibrosis in various nonclinical studies. A phase IIb investigator-initiated clinical trial for lung injury caused by novel coronavirus is being conducted in collaboration with 20 universities and medical institutions in Japan, including Tohoku University, and the clinical study report is scheduled to be prepared in March 2023. Since lung injury can be caused not only by viruses but also by various other causes, such as anticancer drugs, autoimmune diseases, and idiopathic diseases of unknown cause, the Company plans to investigate the efficacy of the drug in clinical trials for lung injury caused by other causes in addition to the novel coronavirus.

As part of this effort, the Company has entered into the Agreement with the Department of Respiratory Medicine, Kyoto University Hospital to start collaboration with a view to conducting a clinical trial for acute exacerbation of idiopathic interstitial pneumonia. Acute exacerbation of idiopathic interstitial pneumonia is a condition with poor prognosis that accounts for approximately 40% of all deaths from idiopathic interstitial pneumonia.

2. Outline of the collaboration partners

(1) Name	Kyoto University
(2) Address	Yoshida Honmachi, Sakyo-ku, Kyoto-shi, Kyoto
(3) Title and Name of Representative	President Nagahiro Minato
(4) Capital	157.7 billion yen
(5) Date of Establishment	Establishment of Kyoto University as a national university corporation as of April 2004 (Kyoto University established in June 1897)
(6) Relationship with Kyoto University	Kyoto University and the Company have been jointly

	<p>conducting research and development of support system for the respiratory function test (spirometry) utilizing artificial intelligence (AI).</p> <p>Kyoto University and the Company have also conducted the investigator-initiated clinical trials (Phase IIa and IIb) for lung injury caused by novel coronavirus together with several universities and medical institutions.</p> <p>There are no other capital relationships, personal relationships, or related party relationships.</p>
--	--

3. Outlook for the future

This matter will have no impact on the forecast of business results for the fiscal year ending March 31, 2023.

End